XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Breast Trials

A LIST OF OUR EARLY PHASE Breast cancer TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALs

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

 

D967JC00001 DESTINY-Breast07

T-DXd given with other treatments in HER2+ metastatic breast cancer:  A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY Breast07)

Local Project Reference:135544
Principal InvestigatorDr. Rebecca Roylance
Drug Class/ Treatment:

Trastuzumab Deruxtecan (T-DXd) - Antibody-Drug Conjugate

Monotherapy and/or Combination with Chemotherapy and/or Immunotherapy

Patient Population:HER2-Positive Breast Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

GS-US-586-6144

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Local Project Reference:305446
Principal InvestigatorDr Elisavet Papadimitraki
Drug Class/ Treatment:

Magrolimab - Monoclonal Antibody against CD47 and Macrophage Checkpoint Inhibitor

Safety Run-In Cohort 2: Magrolimab + Sacituzumab Govitecan 

Phase 2 Cohort 1 Arm A: Magrolimab + Nab-Paclitaxel or Paclitaxel

Phase 2 Cohort 1 Arm B: Nab-Paclitaxel or Paclitaxel

Patient Population:Locally Advanced or Metastatic Triple-Negative Breast Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)